IBDEI19N ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21171,1,4,0)
 ;;=4^I69.091
 ;;^UTILITY(U,$J,358.3,21171,2)
 ;;=^5007421
 ;;^UTILITY(U,$J,358.3,21172,0)
 ;;=I69.891^^101^1027^26
 ;;^UTILITY(U,$J,358.3,21172,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21172,1,3,0)
 ;;=3^Dysphagia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,21172,1,4,0)
 ;;=4^I69.891
 ;;^UTILITY(U,$J,358.3,21172,2)
 ;;=^5007547
 ;;^UTILITY(U,$J,358.3,21173,0)
 ;;=I69.321^^101^1027^27
 ;;^UTILITY(U,$J,358.3,21173,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21173,1,3,0)
 ;;=3^Dysphasia following cerebral infarction
 ;;^UTILITY(U,$J,358.3,21173,1,4,0)
 ;;=4^I69.321
 ;;^UTILITY(U,$J,358.3,21173,2)
 ;;=^5007492
 ;;^UTILITY(U,$J,358.3,21174,0)
 ;;=I69.121^^101^1027^28
 ;;^UTILITY(U,$J,358.3,21174,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21174,1,3,0)
 ;;=3^Dysphasia following nontraumatic intracerebral hemorrhage
 ;;^UTILITY(U,$J,358.3,21174,1,4,0)
 ;;=4^I69.121
 ;;^UTILITY(U,$J,358.3,21174,2)
 ;;=^5007428
 ;;^UTILITY(U,$J,358.3,21175,0)
 ;;=I69.021^^101^1027^29
 ;;^UTILITY(U,$J,358.3,21175,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21175,1,3,0)
 ;;=3^Dysphasia following nontraumatic subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,21175,1,4,0)
 ;;=4^I69.021
 ;;^UTILITY(U,$J,358.3,21175,2)
 ;;=^5007396
 ;;^UTILITY(U,$J,358.3,21176,0)
 ;;=I69.821^^101^1027^31
 ;;^UTILITY(U,$J,358.3,21176,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21176,1,3,0)
 ;;=3^Dysphasia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,21176,1,4,0)
 ;;=4^I69.821
 ;;^UTILITY(U,$J,358.3,21176,2)
 ;;=^5007523
 ;;^UTILITY(U,$J,358.3,21177,0)
 ;;=I69.221^^101^1027^30
 ;;^UTILITY(U,$J,358.3,21177,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21177,1,3,0)
 ;;=3^Dysphasia following oth nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,21177,1,4,0)
 ;;=4^I69.221
 ;;^UTILITY(U,$J,358.3,21177,2)
 ;;=^5007460
 ;;^UTILITY(U,$J,358.3,21178,0)
 ;;=G11.1^^101^1027^32
 ;;^UTILITY(U,$J,358.3,21178,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21178,1,3,0)
 ;;=3^Early-onset cerebellar ataxia
 ;;^UTILITY(U,$J,358.3,21178,1,4,0)
 ;;=4^G11.1
 ;;^UTILITY(U,$J,358.3,21178,2)
 ;;=^5003753
 ;;^UTILITY(U,$J,358.3,21179,0)
 ;;=I69.392^^101^1027^33
 ;;^UTILITY(U,$J,358.3,21179,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21179,1,3,0)
 ;;=3^Facial weakness following cerebral infarction
 ;;^UTILITY(U,$J,358.3,21179,1,4,0)
 ;;=4^I69.392
 ;;^UTILITY(U,$J,358.3,21179,2)
 ;;=^5007517
 ;;^UTILITY(U,$J,358.3,21180,0)
 ;;=I69.192^^101^1027^34
 ;;^UTILITY(U,$J,358.3,21180,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21180,1,3,0)
 ;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
 ;;^UTILITY(U,$J,358.3,21180,1,4,0)
 ;;=4^I69.192
 ;;^UTILITY(U,$J,358.3,21180,2)
 ;;=^5007454
 ;;^UTILITY(U,$J,358.3,21181,0)
 ;;=I69.292^^101^1027^36
 ;;^UTILITY(U,$J,358.3,21181,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21181,1,3,0)
 ;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
 ;;^UTILITY(U,$J,358.3,21181,1,4,0)
 ;;=4^I69.292
 ;;^UTILITY(U,$J,358.3,21181,2)
 ;;=^5007486
 ;;^UTILITY(U,$J,358.3,21182,0)
 ;;=I69.092^^101^1027^35
 ;;^UTILITY(U,$J,358.3,21182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21182,1,3,0)
 ;;=3^Facial weakness following ntrm subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,21182,1,4,0)
 ;;=4^I69.092
 ;;^UTILITY(U,$J,358.3,21182,2)
 ;;=^5007422
 ;;^UTILITY(U,$J,358.3,21183,0)
 ;;=I69.892^^101^1027^37
 ;;^UTILITY(U,$J,358.3,21183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21183,1,3,0)
 ;;=3^Facial weakness following other cerebrovascular disease
